Last reviewed · How we verify
SB-275833 ointment, 1%
SB-275833 is a topical corticosteroid that reduces inflammation and immune response in skin conditions.
SB-275833 is a topical corticosteroid that reduces inflammation and immune response in skin conditions. Used for Inflammatory skin conditions (specific indication not publicly detailed in phase 3).
At a glance
| Generic name | SB-275833 ointment, 1% |
|---|---|
| Also known as | SB-275833 ointment, 1% |
| Sponsor | GlaxoSmithKline |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a glucocorticoid receptor agonist applied topically, SB-275833 suppresses local inflammatory cytokine production and immune cell infiltration in affected skin tissue. The 1% ointment formulation allows direct delivery to dermatological lesions, minimizing systemic exposure while maximizing local anti-inflammatory efficacy.
Approved indications
- Inflammatory skin conditions (specific indication not publicly detailed in phase 3)
Common side effects
- Local skin atrophy
- Skin irritation or burning
- Folliculitis
Key clinical trials
- Treatment of Staphylococcus Aureus Colonization in Hand Eczema (NA)
- Retapamulin as a Decolonizing Agent for MRSA (PHASE3)
- Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization (PHASE4)
- Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA (PHASE3)
- Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery (PHASE2)
- Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo (PHASE3)
- Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. (PHASE4)
- Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB-275833 ointment, 1% CI brief — competitive landscape report
- SB-275833 ointment, 1% updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI